Patents Assigned to Teva Pharmaceutical Fine Chemicals S.r.l
-
Patent number: 7569729Abstract: Stable Atomoxetine hydrochloride, a process for the manufacture thereof, the use of stable Atomoxetine Hydrochloride for making a pharmaceutical formulation, a process for the preparation of any form of Atomoxetine Hydrochloride, and an analytical method for analyzing the stability of Atomoxetine Hydrochloride are provided.Type: GrantFiled: April 5, 2006Date of Patent: August 4, 2009Assignee: Teva Pharmaceutical Fine Chemicals S.R.L.Inventors: Eugenio Castelli, Paolo Riva
-
Patent number: 7507861Abstract: The present invention provides improved processes for the preparation of atomoxetine hydrochloride under reaction conditions that improve reaction yields and facilitate commercial synthesis. In particular, the invention is directed to the synthesis of atomoxetine HCl by adding HCl to a mixture of (R)-(?)-tomoxetine (S)-(+)-mandelate with an organic solvent, with or without a base and water.Type: GrantFiled: June 28, 2005Date of Patent: March 24, 2009Assignee: Teva Pharmaceutical Fine Chemicals, S.r.l.Inventors: Eugenio Castelli, Giuseppe Lo Monaco, Silvia Mantovani, Paola Daverio, Paolo Riva, Alessandra Vailati, Stefano Bianchi
-
Patent number: 7488758Abstract: The invention is directed to levalbuterol HCl Form B and methods of making the same.Type: GrantFiled: May 20, 2005Date of Patent: February 10, 2009Assignee: Teva Pharmaceutical Fine Chemicals, S.r.l.Inventors: Valeriano Merli, Silvia Mantovani, Stefano Bianchi, Paola Daverio, Angelo Spreafico, Judith Aronhime, Adrienne Kovacsne-Mezei
-
Patent number: 7482489Abstract: Provided are processes for the preparation of (R)-SLB.D-DBTA salt and levalbuterol hydrochloride. Also provided are levalbuterol hydrochloride degradation products and processes for preparing them. Pharmaceutical compositions comprising at least one levalbuterol hydrochloride of the invention and at least one pharmaceutically-acceptable excipient are also provided.Type: GrantFiled: May 20, 2005Date of Patent: January 27, 2009Assignee: Teva Pharmaceutical Fine Chemicals S.r.l.Inventors: Valeriano Merli, Silvia Mantovani, Stefano Bianchi, Paola Daverio
-
Patent number: 7473804Abstract: The present invention provides novel crystalline polymorph forms of atomoxetine hydrochloride denominated Forms B and C and methods for their preparation, as well as methods for the preparation of Form A. The present invention provides pharmaceutical compositions that comprise atomoxetine hydrochloride Form B, Form C, or mixtures thereof that can be used to treat attention deficit/hyperactivity disorder.Type: GrantFiled: July 21, 2005Date of Patent: January 6, 2009Assignee: Teva Pharmaceutical Fine Chemicals s.r.l.Inventors: Judith Aronhime, Stefano Bianchi, Eugenio Castelli, Paola Daverio, Silvia Mantovani, Adrienne Kovacsne-Mezei
-
Patent number: 7465831Abstract: The invention is directed to processes for making levalbuterol HCl Polymorph A from by suspending or forming a first slurry of (R)-SLB(D)-DBTA in at least a first organic solvent, adding HCl to the suspension or slurry of the solid (R)-SLB.D-DBTA until the (R)-SLB.D-DBTA forms levalbuterol HCl Polymorph A, and isolating the levalbuterol HCl Polymorph A.Type: GrantFiled: July 11, 2007Date of Patent: December 16, 2008Assignee: Teva Pharmaceutical Fine Chemicals s.r.l.Inventors: Valeriano Merli, Silvia Mantovani, Stefano Bianchi, Paola Daverio, Angelo Spreafico, Judith Aronhime, Adrienne Kovacsne-Mezei
-
Patent number: 7462743Abstract: A crystalline Form II of memantine hydrochloride, pharmaceutical compositions containing crystalline Form II, and methods of preparing crystalline Forms I and II of memantine hydrochloride are provided.Type: GrantFiled: January 11, 2006Date of Patent: December 9, 2008Assignee: Teva Pharmaceutical Fine Chemicals S.r.l.Inventors: Valeriano Merli, Paola Daverio, Adrienne Kovacsne-Mezei, Judith Aronhime
-
Patent number: 7439398Abstract: The present invention provides enantiomerically pure (R)-(?)-tomoxetine (S)-(+)-mandelate and atomoxetine HCl. The present invention further provides enantiomerically pure (R)-(?)-tomoxetine (S)-(+)-mandelate prepared from racemic tomoxetine. The present invention also provides enantiomerically pure atomoxetine HCl prepared from (R)-(?)-tomoxetine (S)-(+)-mandelate.Type: GrantFiled: June 28, 2005Date of Patent: October 21, 2008Assignee: Teva Pharmaceutical Fine Chemicals S.R.L.Inventors: Eugenio Castelli, Paola Daverio, Silvia Mantovani
-
Patent number: 7378553Abstract: The present invention provides isolated N-methyl-3-(3-methylphenoxy)-3-phenylpropylamine hydrochloride, and preparation thereof as well as of N-methyl-3-(4-methylphenoxy)-3-phenylpropylamine hydrochloride and of N-methyl-3-phenoxy-3-phenylpropylamine hydrochloride. The invention further provides the use of the above compounds as reference markers and/or reference standards during the synthesis of Atomoxetine. Also provided is a method of limiting the amounts of the impurities 3FT (3-fluorotoluene), 4FT (4-fluorotoluene), and FB (fluorobenzene) in the 2-fluorotoluene starting material used in the synthesis of Atomoxetine Hydrochloride. The purity of the Atomoxetine Hydrochloride product is ensured by determining the amounts of 3FT, 4FT, and FB in the 2-fluorotoluene starting material with the marker 3-ATM HCl.Type: GrantFiled: June 28, 2005Date of Patent: May 27, 2008Assignee: Teva Pharmaceutical Fine Chemicals S.r.l.Inventors: Eugenio Castelli, Alessandra Vailati
-
Patent number: 7355078Abstract: Provided are processes for preparing tomoxetine comprising reacting N-methyl-3-hydroxy-3-phenylpropylamine with dimethylsulfoxide (DMSO) and 2-fluorotoluene in the presence of an alkali base to form tomoxetine. Also provided is the conversion of said tomoxetine into atomoxetine or a pharmaceutically acceptable salt thereof.Type: GrantFiled: June 28, 2005Date of Patent: April 8, 2008Assignee: Teva Pharmaceutical Fine Chemicals S.r.l.Inventors: Eugenio Castelli, Giuseppe Lo Monaco, Silvia Mantovani, Paola Daverio, Paolo Riva, Alessandra Vailati, Stefano Bianchi
-
Patent number: 7317127Abstract: The present invention provides a process for the optical resolution of racemic tomoxetine under reaction conditions that improve reaction yields and optical purity. The invention also provides an epimerization process for the (S)-(+) enantiomer. The invention further provides the conversion of the enantiomer obtained from the optical resolution into atomoxetine or a pharmaceutically acceptable salt thereof.Type: GrantFiled: June 28, 2005Date of Patent: January 8, 2008Assignee: Teva Pharmaceutical Fine Chemicals S.r.lInventors: Eugenio Castelli, Giuseppe Lo Monaco, Silvia Mantovani, Paola Daverio, Paolo Riva, Alessandra Vailati, Stefano Bianchi